Policy

  • Metabolic liver disease to affect almost 2bn by 2050

    Metabolic liver disease to affect almost 2bn by 2050

    Liver disease linked to obesity and high blood sugar could affect 1.8bn people worldwide by 2050, a study suggests. Metabolic dysfunction-associated steatotic liver disease, or MASLD, was previously known as non-alcoholic fatty liver disease. It is one of the most common and fastest-growing liver conditions worldwide. There are now 1.3bn people worldwide living with MASLD, [...]

  • Gut health supplement relieves arthritis pain, research finds

    Gut health supplement relieves arthritis pain, research finds

    A prebiotic fibre supplement may ease arthritis pain and improve grip strength in people with knee osteoarthritis, a study suggests. The daily supplement, made from inulin, a dietary fibre found in chicory root, Jerusalem artichokes and other vegetables, also lowered pain sensitivity and saw fewer people drop out than a digital physiotherapy programme tested alongside [...]

  • Scottish Medicines Consortium rejects Alzheimer’s therapy

    Scottish Medicines Consortium rejects Alzheimer’s therapy

    The Scottish Medicines Consortium has declined to recommend the Alzheimer's therapy donanemab (Kisunla, Eli Lilly) for early-stage disease in NHS Scotland. The decision affects patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease who are apolipoprotein E epsilon 4 heterozygotes or non-carriers, a genetic marker. The consortium cited uncertainty over clinical relevance [...]